Resumen de The clinical features and prognostic implications of the co‑mutated TP53 gene in advanced non‑small cell lung cancer

Bing Bai, Xia An, Qinghui Qu, Xin Liu, Yuanyuan Liu, Li Wei

• Background TP53 is a frequently mutated oncogene within non-small cell lung cancer (NSCLC). However, the clinical and prognostic signifcance of co-mutations in TP53 in patients with advanced NSCLC has not been fully elucidated.

  Methods A total of 174 patients with advanced NSCLC were enrolled in this study. All patients were subjected to sequencing analysis of tumor-related genes and information such as PD-L1 expression, TMB, and co-mutation changes were collected. Patients were categorized into TP53 mutant and TP53 wild-type groups according to their TP53 mutation status and then statistically analyzed.

  Results TP53 mutations were the most common among all patients, accounting for 56.32%, followed by epidermal growth factor receptor mutations at 48.27%. The most common mutation sites in the TP53 mutation group were exons 5–8.TP53 mutations were signifcantly associated with PD-L1 and TMB levels. Univariate Cox analysis showed that gender and EGFR mutation afected the prognosis of TP53-mutated NSCLC patients, and multivariate Cox regression analysis identifed EGFR mutation as an independent risk factor. The OS of NSCLC patients in the TP53 mutation group was signifcantly shorter than that of the TP53wt group. Survival curves in the TP53/EGFR combined mutation group showed that patients with combined EGFR mutation had a lower survival rate.

  Discussion TP53 mutations are associated with diferent clinical indicators and have important implications in clinical treatment. TP53 is a poor prognostic factor for NSCLC patients, and TP53/EGFR co-mutation will afect the survival time of patients. TP53/EGFR co-mutation may be a new prognostic marker for NSCLC.